Unicycive Therapeutics
Steve Hasal has extensive work experience in the pharmaceutical and medical writing fields. Steve is currently employed as the Sr. Director of Clinical Sciences at Unicycive Therapeutics since December 2022. Prior to their current role, they worked at Spectrum Pharmaceuticals, Inc. for eight years, starting as a Contract Medical Writer from January 2014 to September 2014, followed by roles as Director and Sr. Director of Medical Writing and Publications from September 2014 to December 2022. Steve also served as a Clinical Scientist at Merck: Legacy Schering-Plough from November 2010 to November 2013 and as a Senior Medical Writer at Schering-Plough Research Institute from November 2004 to November 2010. Before that, they held the position of President at SciMed Communications, Inc. from 2000 to 2004. Steve began their career at Novartis as a Senior Scientist from 1998 to 2000.
Steve Hasal received their Bachelor of Arts degree in Biochemistry from the University of Arizona. Steve then went on to pursue their higher education and obtained a PhD in Pharmacology and Toxicology, also from the University of Arizona.
This person is not in any offices
Unicycive Therapeutics
Unicycive Therapeutics provides development programs that focus on treating kidney diseases with significant unmet medical needs. It aims to open the way for a broad range of disease-modifying therapies by modifying the intracellular and extracellular concentrations of these various electrolytes and ions in Chronic Kidney Disease and Gitelman’sSyndrome and by addressing the underlying mitochondrial pathology and inflammation associated with Acute Kidney Disease.Unicycive Therapeutics was founded in 2016 and is headquartered in Los Altos, California.